Rockwell Medical (RMTI) Expected to Announce Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Rockwell Medical to post earnings of ($0.13) per share and revenue of $18.22 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Rockwell Medical had a negative return on equity of 14.03% and a negative net margin of 7.33%. The company had revenue of $17.78 million during the quarter, compared to analyst estimates of $17.82 million. On average, analysts expect Rockwell Medical to post ($0.90) EPS for the current fiscal year and $0.36 EPS for the next fiscal year.

Rockwell Medical Price Performance

Rockwell Medical stock opened at $7.31 on Wednesday. Rockwell Medical has a 1 year low of $4.89 and a 1 year high of $12.90. The firm has a 50 day moving average price of $7.85 and a 200 day moving average price of $8.14. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Rockwell Medical in a report on Friday, September 11th. Wall Street Zen raised shares of Rockwell Medical to a “hold” rating in a research note on Saturday, July 25th. Zacks Research downgraded Rockwell Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Weiss Ratings raised Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $20.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.